Advanced search
1 file | 3.92 MB Add to list

Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection

Leen Vancoillie (UGent) , Els Demecheleer (UGent) , Steven Callens (UGent) , Dirk Vogelaers (UGent) , Linos Vandekerckhove (UGent) , Virginie Mortier (UGent) and Chris Verhofstede (UGent)
Author
Organization
Abstract
To identify host and viral characteristics associated with long-term persisting low-level viraemia (PLLV) under antiretroviral therapy (ART). Seventy-one ART-treated patients with long-term PLLV (20250 copies/mL) and 102 control patients with systematically undetectable viral load (VL) were selected retrospectively from ART-treated patients followed at the Ghent HIV reference centre. Host and viral characteristics were compared using univariate and multivariate analyses. Higher plasma VL at therapy initiation (OR 3.52; 95 CI 1.866.65; P0.001), therapy re-initiation after an interruption (OR 3.94; 95 CI 1.709.16; P0.001), male gender (OR 4.28; 95 CI 1.4013.00; P0.011), a protease inhibitor-based regimen (OR 2.90; 95 CI 1.206.97; P0.017) and predicted CCR5 co-receptor tropism (OR 2.53; 95 CI 1.056.11; P0.039) were independently associated with PLLV. VL at ART initiation, therapy history, gender, ART regimen and co-receptor tropism were independently associated with PLLV. Gender, therapy history, co-receptor tropism and VL at ART initiation could be valuable predictive markers to identify patients at risk for PLLV.
Keywords
HIV, HAART-TREATED PATIENTS, VIRAL LOAD, HIV-1-INFECTED PATIENTS, RESIDUAL VIREMIA, VIROLOGICAL FAILURE, ULTRASENSITIVE ASSESSMENT, PLASMA VIREMIA, CD4 CELL COUNT, REAL-TIME PCR, DRUG-RESISTANCE MUTATIONS, therapy response, viral load

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 3.92 MB

Citation

Please use this url to cite or link to this publication:

MLA
Vancoillie, Leen, Els Demecheleer, Steven Callens, et al. “Markers Associated with Persisting Low-level Viraemia Under Antiretroviral Therapy in HIV-1 Infection.” JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 69.4 (2014): 1098–1103. Print.
APA
Vancoillie, L., Demecheleer, E., Callens, S., Vogelaers, D., Vandekerckhove, L., Mortier, V., & Verhofstede, C. (2014). Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(4), 1098–1103.
Chicago author-date
Vancoillie, Leen, Els Demecheleer, Steven Callens, Dirk Vogelaers, Linos Vandekerckhove, Virginie Mortier, and Chris Verhofstede. 2014. “Markers Associated with Persisting Low-level Viraemia Under Antiretroviral Therapy in HIV-1 Infection.” Journal of Antimicrobial Chemotherapy 69 (4): 1098–1103.
Chicago author-date (all authors)
Vancoillie, Leen, Els Demecheleer, Steven Callens, Dirk Vogelaers, Linos Vandekerckhove, Virginie Mortier, and Chris Verhofstede. 2014. “Markers Associated with Persisting Low-level Viraemia Under Antiretroviral Therapy in HIV-1 Infection.” Journal of Antimicrobial Chemotherapy 69 (4): 1098–1103.
Vancouver
1.
Vancoillie L, Demecheleer E, Callens S, Vogelaers D, Vandekerckhove L, Mortier V, et al. Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2014;69(4):1098–103.
IEEE
[1]
L. Vancoillie et al., “Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection,” JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 69, no. 4, pp. 1098–1103, 2014.
@article{4661908,
  abstract     = {To identify host and viral characteristics associated with long-term persisting low-level viraemia (PLLV) under antiretroviral therapy (ART).
Seventy-one ART-treated patients with long-term PLLV (20250 copies/mL) and 102 control patients with systematically undetectable viral load (VL) were selected retrospectively from ART-treated patients followed at the Ghent HIV reference centre. Host and viral characteristics were compared using univariate and multivariate analyses.
Higher plasma VL at therapy initiation (OR 3.52; 95 CI 1.866.65; P0.001), therapy re-initiation after an interruption (OR 3.94; 95 CI 1.709.16; P0.001), male gender (OR 4.28; 95 CI 1.4013.00; P0.011), a protease inhibitor-based regimen (OR 2.90; 95 CI 1.206.97; P0.017) and predicted CCR5 co-receptor tropism (OR 2.53; 95 CI 1.056.11; P0.039) were independently associated with PLLV.
VL at ART initiation, therapy history, gender, ART regimen and co-receptor tropism were independently associated with PLLV. Gender, therapy history, co-receptor tropism and VL at ART initiation could be valuable predictive markers to identify patients at risk for PLLV.},
  author       = {Vancoillie, Leen and Demecheleer, Els and Callens, Steven and Vogelaers, Dirk and Vandekerckhove, Linos and Mortier, Virginie and Verhofstede, Chris},
  issn         = {0305-7453},
  journal      = {JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY},
  keywords     = {HIV,HAART-TREATED PATIENTS,VIRAL LOAD,HIV-1-INFECTED PATIENTS,RESIDUAL VIREMIA,VIROLOGICAL FAILURE,ULTRASENSITIVE ASSESSMENT,PLASMA VIREMIA,CD4 CELL COUNT,REAL-TIME PCR,DRUG-RESISTANCE MUTATIONS,therapy response,viral load},
  language     = {eng},
  number       = {4},
  pages        = {1098--1103},
  title        = {Markers associated with persisting low-level viraemia under antiretroviral therapy in HIV-1 infection},
  url          = {http://dx.doi.org/10.1093/jac/dkt484},
  volume       = {69},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: